Charles River Laboratories International (CRL) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Charles River Laboratories International (CRL) overview

Charles River Laboratories International (CRL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 4,015m and operating profit of USD 25.2m; the year-end share price was 203.66 USD and market capitalisation was USD 10,024m. Charles River Laboratories International is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Charles River Laboratories International's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 3,165mFY 2025
Share price203.66 USDFY 2025 year end
RevenueUSD 4,015mFY 2025
Operating profitUSD 25.2mFY 2025
Net earningsUSD -144mFY 2025
Market capitalisationUSD 10,024mFY 2025 year end

About Charles River Laboratories International

Charles River Laboratories supplies research models and services, preclinical drug discovery and safety assessment, and laboratory testing. Its offerings include animal models, research facility support, nonclinical studies, microbial detection and testing products, and specialized biologics testing. Pharmaceutical and biotechnology companies, government agencies, and other research organizations use its products and services to support drug research, development, and quality control.

Generate the Charles River Laboratories International report

Charles River Laboratories International is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Charles River Laboratories International and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Charles River Laboratories International

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.